Literature DB >> 24699989

Spinal non-Hodgkin's lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature.

Sara Monti1, Nicola Boffini2, Marco Lucioni3, Marco Paulli3, Carlomaurizio Montecucco2, Roberto Caporali2.   

Abstract

We report the case of a 52-year-old man with long-standing HLAB27-positive ankylosing spondylitis treated with anti-tumour necrosis factor (TNF) alpha therapy who was admitted to our rheumatology department complaining of increasing lumbar and buttock pain radiating to the posterior thigh, associated with numbness in the leg, gait disturbance and low-grade fever. The clinical picture was initially interpreted as a flare of disease but was not responsive to treatment. A contrast-enhanced spinal MRI was performed with evidence of a diffuse signal abnormality involving the sacroiliac joints and the spine, with evidence of spondylodiscitis of L5 and with a lesion causing L5-S1 root compression and infiltrating the iliopsoas muscle. These findings confirmed the possibility of a reactivation of disease associated with an infectious process. The most frequent causes of infectious spondylodiscitis were excluded, and a biopsy was then performed. Histological analysis revealed a high-grade B-cell non-Hodgkin's lymphoma of the spine. This case highlights how a differential diagnosis of low back pain with neurological symptoms can be particularly troublesome in ankylosing spondylitis and that continuous vigilance is warranted in patients treated with long-term immunosuppressive therapies.

Entities:  

Keywords:  Ankylosing spondylitis; Anti-TNF alpha; Lymphoma; Spondylodiscitis

Mesh:

Substances:

Year:  2014        PMID: 24699989     DOI: 10.1007/s10067-014-2594-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.

Authors:  Kenan Aksu; Ayhan Donmez; Yesim Ertan; Gokhan Keser; Vedat Inal; Gonca Oder; Murat Tombuloglu; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Rheumatol Int       Date:  2007-07-11       Impact factor: 2.631

2.  Ankylosing spondylitis accompanying with Hodgkin's lymphoma.

Authors:  Yun S Kim; Hyun-Sook Kim
Journal:  Int J Rheum Dis       Date:  2012-02-21       Impact factor: 2.454

3.  Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.

Authors:  Xenofon Baraliakos; Joachim Listing; Claudia Fritz; Hildrun Haibel; Rieke Alten; Gerd-Rüdiger Burmester; Andreas Krause; Stefan Schewe; Matthias Schneider; Helmut Sörensen; Reinhold Schmidt; Joachim Sieper; Juergen Braun
Journal:  Rheumatology (Oxford)       Date:  2011-06-14       Impact factor: 7.580

4.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

5.  Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.

Authors:  Kenan Aksu; Seckin Cagirgan; Nazan Ozsan; Gokhan Keser; Fahri Sahin
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 2.631

6.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

7.  Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry.

Authors:  Francesca Bobbio Pallavicini; Roberto Caporali; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Chiara Bazzani; Roberto Gorla; Antonio Marchesoni; Ennio Giulio Favalli; Carlomaurizio Montecucco
Journal:  Autoimmun Rev       Date:  2009-07-30       Impact factor: 9.754

8.  Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.

Authors:  X Mariette; F Tubach; H Bagheri; M Bardet; J M Berthelot; P Gaudin; D Heresbach; A Martin; T Schaeverbeke; D Salmon; M Lemann; O Hermine; M Raphael; P Ravaud
Journal:  Ann Rheum Dis       Date:  2009-10-14       Impact factor: 19.103

9.  Septic Discitis.

Authors:  G A McCain; M Harth; D A Bell; T F Disney; T Austin; E Ralph
Journal:  J Rheumatol       Date:  1981 Jan-Feb       Impact factor: 4.666

10.  Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Authors:  Loreto Carmona; Juan J Gómez-Reino
Journal:  Arthritis Res Ther       Date:  2006-04-18       Impact factor: 5.156

View more
  2 in total

1.  Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.

Authors:  Gregory S Calip; Pritesh R Patel; Sruthi Adimadhyam; Shan Xing; Zhaoju Wu; Karen Sweiss; Glen T Schumock; Todd A Lee; Brian C-H Chiu
Journal:  Int J Cancer       Date:  2018-04-16       Impact factor: 7.396

2.  Intestinal Peripheral T-Cell Lymphoma in a Patient with Ankylosing Spondylitis Under Treatment with Infliximab: A Case Report and Review of the Literature.

Authors:  Firdevs Ulutaş; Cansu Korkmaz; Halil Yılmaz; Duygu Akça; Erdem Çomut; Mustafa Çelık; Veli Çobankara
Journal:  Mediterr J Rheumatol       Date:  2022-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.